Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of May 2021

Commission File Number 001-39670






6 Tide Street, Suite 400

Boston, Massachusetts 02210

Attention: Chief Executive Officer

(617) 482-2333

(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





On May 27, 2021, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) issued a press release announcing the results of its 2021 Annual General Meeting. The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company’s website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.

The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.


99.1    Press Release, dated May 27, 2021, “Results of Annual General Meeting”


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: May 27, 2021   By:  

/s/ Daphne Zohar

    Name:   Daphne Zohar
    Title:   Chief Executive Officer

Exhibit 99.1

27 May 2021

PureTech Health plc

Results of Annual General Meeting

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Thursday, May 27, 2021. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.













   Total votes

001. To approve the Company’s Annual Report and Accounts for year ended 31 December 2020

   225,240,798    100.00%    10,921    0.00%    273,846      225,251,719  

002. To approve the Directors’ Remuneration Report

   200,319,991    89.74%    22,895,826    10.26%    2,309,748      223,215,817  

003. To approve the Directors’ Remuneration Policy

   187,285,809    83.90%    35,930,008    16.10%    2,309,748      223,215,817  

004. To elect Dr. Raju Kucherlapati as a director

   222,659,203    98.73%    2,865,525    1.27%    837      225,524,728  

005. To elect Dr. John LaMattina as a director

   218,438,727    96.86%    7,086,001    3.14%    837      225,524,728  

006. To elect Ms. Kiran Mazumdar-Shaw as a director

   189,257,653    84.32%    35,193,037    15.68%    1,074,875      224,450,690  

007. To elect Dame Marjorie Scardino as a director

   222,228,072    98.54%    3,296,656    1.46%    837      225,524,728  

008. To elect Mr. Christopher Viehbacher as a director

   199,985,210    88.68%    25,539,518    11.32%    837      225,524,728  

009. To elect Dr. Robert Langer as a director

   218,164,180    96.74%    7,360,548    3.26%    837      225,524,728  

010. To elect Ms. Daphne Zohar as a director

   225,474,510    99.98%    50,218    0.02%    837      225,524,728  

011. To elect Dr. Bharatt Chowrira as a director

   225,473,830    99.98%    50,898    0.02%    837      225,524,728  












   Total votes

012. To reappoint KPMG LLP as Auditors of the Company

   225,291,096    99.90%    234,469    0.10%    0      225,525,565  

013. To authorize the Audit Committee to determine the Auditors’ remuneration

   225,483,695    99.98%    41,870    0.02%    0      225,525,565  

014. To authorize the allotment of shares

   221,538,872    98.23%    3,986,693    1.77%    0      225,525,565  

015. To disapply pre-emption rights

   225,102,915    99.81%    422,650    0.19%    0      225,525,565  

016. To further disapply pre-emption rights for acquisitions and specified capital investments.

   215,316,258    95.47%    10,209,307    4.53%    0      225,525,565  

017. To authorize market purchase of own shares

   225,235,005    99.89%    258,692    0.11%    31,868      225,493,697  

018. To authorize general meetings to be called on not less than 14 clear days’ notice

   222,063,258    98.46%    3,462,307    1.54%    0      225,525,565  




A vote “Withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.



As at May 27, 2021 the number of issued shares in the Company was 286,018,538 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.



The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company’s website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, is comprised of 26 therapeutics and therapeutic candidates, including two that have received FDA clearance and European marketing authorization, as of the date of PureTech’s most recently filed Annual Report on Form 20-F. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company’s unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.




Allison Mead Talbot   
+1 617 651 3156